デノスマブの世界市場レポート 2024

デノスマブ市場規模は、今後数年で急成長が見込まれます。2028年にはCAGR11.5％で50億6,000万米ドルに成長します。予測期間中に予想される成長は、骨転移の発生率の上昇、がん治療の進歩、骨粗鬆症の有病率、骨粗鬆症関連の問題に対する意識の高まり、新しい適応症に対する規制当局の承認などの要因によるものと考えられます。予測期間中に予想される主な動向としては、製薬業界における戦略的提携やパートナーシップ、患者ケアの向上を目的としたデジタルヘルスソリューションとの統合、デノスマブの適応拡大や臨床応用、治療選択肢の拡大を目的としたバイオシミラー開発の進展などが挙げられます。

骨粗鬆症の有病率の上昇は、今後数年間のデノスマブ市場の拡大を促進すると予測されています。骨粗鬆症は、骨の弱化と骨密度の低下を特徴とし、骨折への感受性を高める。デノスマブは、RANKリガンドを標的とする薬剤で、骨吸収プロセスを阻止することにより骨粗鬆症の治療に利用されます。オーストラリア保健福祉研究所（AIHW）の2023年12月の報告書で強調されたように、骨粗鬆症は2021年に2,366人の死亡に寄与し、これは10万人当たり6.5人の死亡に相当し、総死亡の1.4％を占める。さらに、2021年から22年にかけて、骨粗鬆症と診断された45歳以上の入院患者数は9,500人で、人口10万人当たり89人が入院しています。このように、骨粗鬆症の有病率の上昇は、デノスマブ市場成長の促進要因となっています。

デノスマブ市場の主要プレーヤーは、競争上の優位性を獲得するために、革新的なソリューション、特に骨粗鬆症のファーストライン治療を導入する努力を強めています。骨粗鬆症の第一選択治療とは、骨粗鬆症と診断された患者を管理するためにヘルスケア専門医が推奨する最初の治療アプローチを指します。例えば、2022年11月、中国のバイオテクノロジー企業であるBoan Biotechは、デノスマブのバイオシミラーであるBoyoubeiの承認を中国国家医薬品監督管理局（NMPA）から取得し、デノスマブ注射剤を開発した初の中国企業となった。また、Boyoubeiは、世界なマーケティング戦略により、欧米を含む中国以外の市場にもイントロダクションされる予定です。様々な治療ガイドラインにおいて骨粗鬆症の第一選択薬として位置づけられているBoyoubeiは、骨粗鬆症患者の股関節骨折、非椎体骨折、椎体骨折のリスクを大幅に減少させることが期待されています。特筆すべきは、BoyoubeiがProlia（デノスマブのオリジネーター）のバイオシミラーとして世界で初めて製造販売承認を取得したことです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のデノスマブ市場、薬物分類別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年、2033年
• プロリア
• シュゲヴァ
• その他
• 世界のデノスマブ市場、タイプ別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年、2033年
• 60 mg
• 120 mg
• 世界のデノスマブ市場、エンドユーザー別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年、2033年
• 病院
• 在宅ケア
• 専門クリニック
• 外来手術センター

第7章 地域別・国別分析

• 世界のデノスマブ市場、地域別、実績および予測、2018～2023年、2023～2028年、2033年
• 世界のデノスマブ市場、国別、実績および予測、2018年～2023年、2023年～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• デノスマブ市場の競合情勢
• デノスマブ市場企業プロファイル
  • Johnson &Johnson
  • F. Hoffmann-La Roche Ltd.
  • Novartis International AG
  • Sanofi SA
  • GlaxoSmithKline plc

第31章 その他の大手企業と革新的企業

• Eli Lilly and Company
• Amgen Inc.
• Asahi Kasei Corporation
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Daiichi Sankyo Company, Limited
• Mylan NV
• Sandoz International GmbH
• Daiichi Sankyo Company Limited
• Aurobindo Pharma Limited
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals PLC
• Celltrion Inc.
• Amneal Pharmaceuticals Inc

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在的分析

第36章 付録

Denosumab is a monoclonal antibody employed in the treatment of bone-related conditions, particularly osteoporosis and bone metastases. Its mechanism of action involves inhibiting osteoclast formation, reducing bone resorption, increasing bone mineral density, and consequently lowering the risk of fractures.

The main classifications of denosumab drugs include Prolia, Xgeva, and others. Prolia is a prescription medicine specifically used for treating osteoporosis in postmenopausal women who are at a high risk of fractures or cannot use another osteoporosis medication. This drug is available in 60 mg and 120 mg doses and is utilized by various end-users such as hospitals, home care services, specialty clinics, and ambulatory surgical centers.

The denosumab market research report is one of a series of new reports from The Business Research Company that provides denosumab market statistics, including denosumab industry global market size, regional shares, competitors with a denosumab market share, detailed denosumab market segments, market trends and opportunities, and any further data you may need to thrive in the denosumab industry. This denosumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The denosumab market size has grown rapidly in recent years. It will grow from $2.89 billion in 2023 to $3.27 billion in 2024 at a compound annual growth rate (CAGR) of 13.2%. The growth observed during the historic period can be attributed to various factors, including advancements in clinical trials and research, milestones achieved in FDA approvals and regulatory processes, a growing awareness of bone health, and the impact of strategic partnerships and effective marketing initiatives.

The denosumab market size is expected to see rapid growth in the next few years. It will grow to $5.06 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The anticipated growth in the forecast period can be attributed to factors such as the rising incidence of bone metastases, advancements in cancer therapies, the prevalence of osteoporosis, increased awareness of osteoporosis-related issues, and regulatory approvals for new indications. Major trends expected in the forecast period include strategic collaborations and partnerships within the pharmaceutical industry, integration with digital health solutions for improved patient care, expanded indications and clinical applications of denosumab, and advancements in biosimilar development for enhanced treatment options.

The rising prevalence of osteoporosis is anticipated to drive the expansion of the denosumab market in the coming years. Osteoporosis, characterized by weakened bones and diminished bone density, heightens the susceptibility to fractures. Denosumab, a medication targeting the RANK ligand, is utilized in the treatment of osteoporosis by halting bone resorption processes. As highlighted in a December 2023 report by the Australian Institute of Health and Welfare (AIHW), osteoporosis contributed to 2,366 fatalities in 2021, equating to 6.5 deaths per 100,000 individuals, constituting 1.4% of total deaths. Moreover, during 2021-22, there were 9,500 hospitalizations among individuals aged 45 and above with a primary diagnosis of osteoporosis, translating to 89 hospitalizations per 100,000 population. Thus, the escalating prevalence of osteoporosis acts as a catalyst for the growth of the denosumab market.

Key players within the denosumab market are intensifying their efforts to introduce innovative solutions, particularly first-line treatments for osteoporosis, to gain a competitive advantage. First-line treatment for osteoporosis denotes the initial therapeutic approach recommended by healthcare practitioners for managing individuals diagnosed with the condition. For instance, in November 2022, Boan Biotech, a China-based biotechnology firm, secured approval from China's National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, becoming the first Chinese company to develop a denosumab injection. Boyoubei is also slated for introduction into markets beyond China, including Europe and the United States, with a global marketing strategy in place. Positioned as a first-line treatment option for osteoporosis in various treatment guidelines, Boyoubei holds promise in significantly reducing the risk of hip, non-vertebral, and vertebral fractures among affected individuals. Notably, Boyoubei stands out as the world's first biosimilar to Prolia (the originator of denosumab) to receive marketing approval.

In June 2022, Organon, a pharmaceutical company headquartered in the United States, entered into a partnership with Henlius to commercialize Henlius for an undisclosed sum. This collaboration enables Organon to obtain the commercialization rights for biosimilar candidates referencing Perjeta (Pertuzumab, HLX11) and Prolia or Xgeva (Denosumab). The agreement aligns with Organon's expertise in biosimilar commercialization and its dedication to providing high-quality and cost-effective biologic medicines globally, with a specific focus on women's health. Henlius, a biopharmaceutical company based in China, specializes in the development of Denosumab biosimilars, including HLX14.

Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

North America was the largest region in the denosumab market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the denosumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The denosumab market consists of sales of calcium supplements and vitamin D supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Denosumab Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on denosumab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for denosumab? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The denosumab market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Classification: Prolia; Xgeva; Others
• 2) By Type: 60 mg; 120 mg
• 3) By End-Users: Hospitals; Homecare; Specialty Clinics; Ambulatory Surgical Centers
• Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Novartis International AG; Sanofi SA; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Denosumab Market Characteristics

3. Denosumab Market Trends And Strategies

4. Denosumab Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Denosumab Market Size and Growth

• 5.1. Global Denosumab Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Denosumab Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Denosumab Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Denosumab Market Segmentation

• 6.1. Global Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Prolia
• Xgeva
• Others
• 6.2. Global Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

60 mg

120 mg

• 6.3. Global Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Ambulatory Surgical Centers

7. Denosumab Market Regional And Country Analysis

• 7.1. Global Denosumab Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Denosumab Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Denosumab Market

• 8.1. Asia-Pacific Denosumab Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Denosumab Market

• 9.1. China Denosumab Market Overview
• 9.2. China Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Denosumab Market

• 10.1. India Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Denosumab Market

• 11.1. Japan Denosumab Market Overview
• 11.2. Japan Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Denosumab Market

• 12.1. Australia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Denosumab Market

• 13.1. Indonesia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Denosumab Market

• 14.1. South Korea Denosumab Market Overview
• 14.2. South Korea Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Denosumab Market

• 15.1. Western Europe Denosumab Market Overview
• 15.2. Western Europe Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Denosumab Market

• 16.1. UK Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Denosumab Market

• 17.1. Germany Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Denosumab Market

• 18.1. France Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Denosumab Market

• 19.1. Italy Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Denosumab Market

• 20.1. Spain Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Denosumab Market

• 21.1. Eastern Europe Denosumab Market Overview
• 21.2. Eastern Europe Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Denosumab Market

• 22.1. Russia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Denosumab Market

• 23.1. North America Denosumab Market Overview
• 23.2. North America Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Denosumab Market

• 24.1. USA Denosumab Market Overview
• 24.2. USA Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Denosumab Market

• 25.1. Canada Denosumab Market Overview
• 25.2. Canada Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Denosumab Market

• 26.1. South America Denosumab Market Overview
• 26.2. South America Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Denosumab Market

• 27.1. Brazil Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Denosumab Market

• 28.1. Middle East Denosumab Market Overview
• 28.2. Middle East Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Denosumab Market

• 29.1. Africa Denosumab Market Overview
• 29.2. Africa Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Denosumab Market Competitive Landscape And Company Profiles

• 30.1. Denosumab Market Competitive Landscape
• 30.2. Denosumab Market Company Profiles
  • 30.2.1. Johnson & Johnson
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche Ltd.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Novartis International AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Sanofi SA
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. GlaxoSmithKline plc
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Denosumab Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Amgen Inc.
• 31.3. Asahi Kasei Corporation
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Astellas Pharma Inc.
• 31.6. Daiichi Sankyo Company, Limited
• 31.7. Mylan N.V.
• 31.8. Sandoz International GmbH
• 31.9. Daiichi Sankyo Company Limited
• 31.10. Aurobindo Pharma Limited
• 31.11. Cipla Limited
• 31.12. Dr. Reddy's Laboratories Ltd.
• 31.13. Hikma Pharmaceuticals PLC
• 31.14. Celltrion Inc.
• 31.15. Amneal Pharmaceuticals Inc

32. Global Denosumab Market Competitive Benchmarking

33. Global Denosumab Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Denosumab Market

35. Denosumab Market Future Outlook and Potential Analysis

• 35.1 Denosumab Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Denosumab Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Denosumab Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer